Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-02

Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy [Phase 3]

View source ↗

Summary

The Phase 3 trial of secukinumab for moderate-severe rotator cuff tendinopathy was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Rotator Cuff Tendinopathy | Phase 3 | Status: TERMINATED | Results posted: 2025-12-02